Forward Pharma Completed Series A+ Fundraising to Advance Two Clinical-Stage Assets

Forward Pharmaceuticals Co., Ltd. has closed A+ round financing with Nanshan SEI Investment (Shenzhen), QIHANG Venture Capital (Beijing), Leaguer, and V-Fund. This round of fund raising will accelerate clinical development of FWD1802.

FWD1802, an oral SERD for ER+ breast cancer, has received IND clearance from both the FDA and NMPA. It demonstrates activity in both ESR1-mutated and wild-type patients, potentially positioning it as a superior alternative to fulvestrant, which requires intramuscular injection. The Phase I trial in China will be led by Fudan University Shanghai Cancer Center.

Forward Pharma is dedicated to the research and development of innovative therapeutics. The company has built integrated platforms that span the entire drug development cycle - from target validation and drug discovery to early development, translational medicine, preclinical studies, and clinical trials.

Headquartered in Shenzhen, China’s pioneering special economic zone, Forward Pharma also maintains operational and R&D teams in Shanghai and Shenzhen. Over the past seven years, the company has developed a robust pipeline comprising over 10 innovative drugs, focusing on major solid tumors and autoimmune diseases.